Clinical Trials on Protease Inhibitor Related Insulin Resistance

Total 3719 results

K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France
Cordgenics, LLC

Active, not recruiting

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer

United States
Dana-Farber Cancer Institute
ImmunityBio, Inc.

Not yet recruiting

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Ovarian Carcinoma | Recurrent Ovary Cancer | Ovarian Carcinoma, Recurrent

United States
Acrivon Therapeutics
GOG Foundation

Recruiting

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Platinum-resistant Ovarian Cancer | Urothelial Carcinoma | Endometrial Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma

United States
pharmaand GmbH

Completed

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer | Other Solid Tumor | Metastatic Castration-Resistant Prostate Cancer

Israel, Italy, Canada, Russian Federation, United Kingdom, Poland
University Health Network, Toronto

Active, not recruiting

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Ovarian Cancer | Recurrent | Platinum-resistant

Canada
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
Atreca, Inc.

Terminated

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Melanoma | Breast Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Acral Lentiginous Melanoma | Platinum-Resistant Fallopian... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
MacroGenics

Recruiting

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Renal Cell Carcinoma | Advanced Solid Tumor | Epithelial Ovarian Cancer | Hepatocellular Cancer | Malignant Melanoma | Pancreatic Ductal Carcinoma | Castration-Resistant Prostatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors

Advanced Malignant Solid Neoplasm | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Advanced Pancreatic Adenocarcinoma | Platinum-Resistant... and other conditions

United States
Exelixis

Active, not recruiting

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States
University Health Network, Toronto

Completed

Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR)

Microsatellite Stable Colorectal Carcinoma | Platinum Resistant Epithelial Ovarian Cancer Type II | Estrogen Receptor Positive and HER2 Negative Breast Cancer

Canada
Sutro Biopharma, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups... and other collaborators

Recruiting

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Australia, Korea, Republic of, Israel, Singapore, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Malignant Peritoneal Neoplasm | Recurrent Endometrial Carcinoma | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Female... and other conditions

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube... and other conditions

United States
Ohio State University Comprehensive Cancer Center
ImmunoGen, Inc.; Clovis Oncology, Inc.

Active, not recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...

United States
Xencor, Inc.
ICON plc

Recruiting

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Ovarian Cancer | Endometrial Cancer | Cervical Carcinoma | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Clear Cell Carcinoma

United States
Incyte Corporation

Completed

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Pancreatic Ductal Adenocarcinoma | Castration Resistant Prostate Cancer | Gastric/ Gastroesophageal Junction | Squamous Carcinoma...

United States, Spain, France, United Kingdom, Italy, Belgium
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Ovarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)

Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary Carcinoma

United States
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Sumitomo Pharma America, Inc.

Terminated

A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Fallopian Tube Cancer | Primary Peritoneal Cancer | Urothelial Carcinoma | Renal Cell Carcinoma (RCC) | Platinum-resistant Ovarian Cancer (PROC) | Serous Epithelial Ovarian Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Ovarian Endometrioid Adenocarcinoma | Endometrial Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | Endometrial Low Grade Endometrioid... and other conditions

United States
Precigen, Inc

Recruiting

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Stage III Fallopian Tube... and other conditions

United States
Ascendis Pharma Oncology Division A/S

Recruiting

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies (IL Believe)

Advanced Solid Tumor | Metastatic Solid Tumor | Platinum-resistant Ovarian Cancer | Locally Advanced Solid Tumor | Post Anti-PD-1 Melanoma | 2L+ Cervical Cancer | Neoadjuvant Melanoma | Neoadjuvant Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Non-Small Cell Lung Cancer | Post Anti-PD-(L)1 Small Cell...

United States, Australia, Korea, Republic of
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
Cancer Research UK
Hummingbird Bioscience

Recruiting

HMBD-001 in Advanced HER3 Positive Solid Tumours

Melanoma | Cervical Cancer | Gastric Cancer | Pancreatic Cancer | Ovarian Cancer | Hepatocellular Carcinoma (HCC) | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Non-small Cell Lung Cancer (NSCLC) | Oesophageal Cancer | RAS Wild Type Colorectal Cancer | Squamous Cell Cancer of the Head and Neck

United Kingdom
Tempest Therapeutics

Completed

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Urothelial Carcinoma | GastroEsophageal Cancer | Triple-Negative Breast Cancer | Metastatic Castration Resistant Prostate...

United States
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Renal Cell Carcinoma | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Castration-resistant Prostate Cancer | Urothelial Carcinoma | Differentiated Thyroid Cancer | Gastroesophageal... and other conditions

United States, Australia, Belgium, France, Germany, Italy, Netherlands, Spain, United Kingdom
Rahul Aggarwal
AstraZeneca

Recruiting

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Endometrial Cancer | Stage III Renal Cell Cancer | Locally Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IV... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Progressive Disease | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Platinum-Resistant Ovarian Carcinoma | High Grade Ovarian... and other conditions

United States
Xencor, Inc.

Recruiting

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Colorectal Cancer | Castration-resistant Prostate Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Ovarian Cancer, Epithelial | TNBC - Triple-Negative Breast Cancer | Renal Cell Carcinoma, Clear Cell | Melanoma Excluding Uveal Melanoma | Non-small Cell Lung Cancer, Squamous or...

United States
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
Corvus Pharmaceuticals, Inc.

Completed

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Renal Cell Cancer | Non-hodgkin Lymphoma | Metastatic Castration Resistant Prostate...

United States, Australia
Daniel Benjamin
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care (PTN_POPS)

Heart Failure | Epilepsy | Pain | Pneumonia | Sepsis | Inflammation | Hypertension | Chronic Kidney Diseases | Hemophilia | Schizophrenia | Central Nervous System Infections | Nosocomial Pneumonia | Insomnia | Anxiety | Bipolar Disorder | Neutropenia | Staphylococcal Infections | Bradycardia | Seizures | Urinary Tract Infections | Pulmonary... and other conditions

United States, Canada, United Kingdom, Israel, Singapore
SOTIO Biotech AG
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Castration-resistant Prostate Cancer | Cutaneous Squamous Cell Carcinoma

Italy, Spain, France, Belgium, Czechia, United States, Poland, Georgia, Hungary
Arcus Biosciences, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer | Merkel Cell Carcinoma | GastroEsophageal Cancer

United States, Australia
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Malignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditions

United States
Karyopharm Therapeutics Inc

Active, not recruiting

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

Acute Myeloid Leukemia (AML) | Metastatic Colorectal Cancer (mCRC) | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Relapsed/Refractory Multiple Myeloma (RRMM) | Higher-Risk Myelodysplastic Syndrome (HR-MDS) | Newly Diagnosed Intermediate/High-Risk MDS

United States, France, Canada, Spain, China
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
M.D. Anderson Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); Iovance Biotherapeutics

Active, not recruiting

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Malignant Solid Neoplasm | Metastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Platinum-Resistant Ovarian Carcinoma | Metastatic Pancreatic Ductal Adenocarcinoma | Metastatic Ovarian Carcinoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico

Clinical Trials on Protease Inhibitor Related Insulin Resistance

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations